According to the new released IQVIA Report, Oncology trial starts reached historically high levels in 2021, up 56% from 2016 and mostly focused on rare cancer indications. Growing understanding of the biology of malignancies allows us to shift towards targeted therapies or enable personalized treatments.
Read more at: Global Oncology Trends 2022
